Business Context and Reporting Period
This Form 8-K was filed by Second Sight Medical Products, Inc. on September 15, 2018. The report details a significant corporate event regarding the receipt of a federal grant to support the development of a visual cortical prosthesis.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The primary financial data point disclosed is the grant award:
- Initial Grant Award: $1.6 million
- Intent to Fund: Up to $6.3 million over five years
- Funding Condition: Subject to annual review and approval
Material Changes
The material change reported is the receipt of a Notice of Award from the National Institutes of Health (NIH) for grant 1UH3NS103442-01. This funding is designated for the "Early Feasibility Clinical Trial of a Visual Cortical Prosthesis."
Guidance, Outlook, and Management Commentary
Management issued a press release on September 18, 2018, confirming the grant's purpose to support the Orion clinical development program. The filing indicates that future funding beyond the initial $1.6 million is contingent upon annual reviews and approvals by the NIH. No specific financial guidance or risk factors beyond the standard grant conditions were detailed in this specific report.
Investor Verification Checklist
- Verify the status of the NIH grant 1UH3NS103442-01 and the timeline for the initial $1.6 million disbursement.
- Review the specific milestones required for annual review to secure the remaining potential $4.7 million in funding.
- Confirm the progress of the Orion clinical development program and the Early Feasibility Clinical Trial.
- Check subsequent filings for any updates on the utilization of grant funds or changes in the funding agreement.